These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

817 related items for PubMed ID: 24269849

  • 1. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q.
    Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
    [Abstract] [Full Text] [Related]

  • 2. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y, Yokoi N, Okamoto M, Ishikawa H, Komuro A, Kato H, Mimura O, Gomi F.
    Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
    [Abstract] [Full Text] [Related]

  • 3. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
    Horwath-Winter J, Bergloeff J, Floegel I, Haller-Schober EM, Schmut O.
    Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
    [Abstract] [Full Text] [Related]

  • 4. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
    Park DI, Shin HM, Lee SY, Lew H.
    Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
    [Abstract] [Full Text] [Related]

  • 5. Changes in ocular higher-order aberrations following botulinum toxin treatment in patients with blepharospasm : BTX improves dry eye in patients with BEB.
    Isshiki Y, Ishikawa H, Mimura O.
    Jpn J Ophthalmol; 2016 Nov; 60(6):486-491. PubMed ID: 27503401
    [Abstract] [Full Text] [Related]

  • 6. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N, Bilen Ş, Topçu Yılmaz P, Evren Kemer Ö.
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [Abstract] [Full Text] [Related]

  • 7. Relations between nonmotor manifestations and motor disorders in patients with benign essential blepharospasm.
    Zhou Y, Wang W, Lin Z, Lin T, Gong L.
    Graefes Arch Clin Exp Ophthalmol; 2023 Dec; 261(12):3615-3623. PubMed ID: 37341835
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ, Pflugfelder SC, Stern ME, Hardten DR, Conway T, Villanueva L, Hollander DA.
    BMC Ophthalmol; 2017 Dec 28; 17(1):265. PubMed ID: 29284427
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
    Huang JF, Yafawi R, Zhang M, McDowell M, Rittenhouse KD, Sace F, Liew SH, Cooper SR, Pickering EH.
    Ophthalmology; 2012 Jul 28; 119(7):e43-50. PubMed ID: 22607938
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Usefulness of double vital staining with 1% fluorescein and 1% lissamine green in patients with dry eye syndrome.
    Yoon KC, Im SK, Kim HG, You IC.
    Cornea; 2011 Sep 28; 30(9):972-6. PubMed ID: 21705877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.